Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody

The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases

(2017) C. Blandizzi et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

The biosimilar road in inflammatory bowel disease: The right way?

(2014) Gionata Fiorino et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

The challenge of indication extrapolation for infliximab biosimilars

(2014) Brian G. Feagan et al.   BIOLOGICALS

Biosimilars: the science of extrapolation

(2014) M. Weise et al.   BLOOD

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

(2014) Yun-Seong Kang et al.   DIGESTIVE DISEASES AND SCIENCES

The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis

(2014) Dae Hyun Yoo   Expert Review of Clinical Immunology

ECCO position challenged by European drug regulators

(2014) Pekka Kurki et al.   Journal of Crohns & Colitis

Biosimilars: In support of extrapolation of indications

(2014) Hans C. Ebbers   Journal of Crohns & Colitis

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

(2014) David J. Shealy et al.   mAbs

Physicochemical characterization of Remsima®

(2014) Soon Kwan Jung et al.   mAbs

Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars

(2014) David Henry et al.   SEMINARS IN ONCOLOGY

Biologic therapies in inflammatory bowel disease

(2014) Lawrence B. Cohen et al.   Translational Research

Einführung und Gebrauch von „biosimilars“ in der Therapie entzündlich-rheumatischer Erkrankungen

(2014) H.-M. Lorenz et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

(2013) Howard Lee   AAPS Journal

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

(2013) M. Rinaudo-Gaujous et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Biosimilars to treat inflammatory arthritis: the challenge of proving identity

(2013) Jonathan Kay et al.   ANNALS OF THE RHEUMATIC DISEASES

Biosimilars in rheumatology: the wind of change

(2013) Christian K Schneider   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Inequities in access to biologic and synthetic DMARDs across 46 European countries

(2013) Polina Putrik et al.   ANNALS OF THE RHEUMATIC DISEASES

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

(2013) A. Nast et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Biosimilars in IBD: hope or expectation?: Table 1

(2013) Krisztina B Gecse et al.   GUT

The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α

(2013) Naoyasu Ueda et al.   INFLAMMATORY BOWEL DISEASES

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint

(2013) Maurizio Cutolo et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Developing Oncology Biosimilars: An Essential Approach for the Future

(2013) Jame Abraham   SEMINARS IN ONCOLOGY

Clinical experience with Zarzio® in Europe: what have we learned?

(2013) Pere Gascón et al.   SUPPORTIVE CARE IN CANCER

Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland

(2013) G. McCarthy et al.   VALUE IN HEALTH

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations

(2013) Paul Chamberlain   Bioanalysis

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Interchangeability, immunogenicity and biosimilars

(2012) Hans C Ebbers et al.   NATURE BIOTECHNOLOGY

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

(2011) Martin Schiestl et al.   NATURE BIOTECHNOLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biosimilars: pharmacovigilance and risk management

(2010) Leyre Zuñiga et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Pharmacovigilance of Biopharmaceuticals

(2009) Thijs J. Giezen et al.   DRUG SAFETY